To the full analysis
Prothena stock: growth
PRTAProthena reported $9.68M in revenue for fiscal 2025, down 92.8% on the prior year, up 62.6% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
14.7%
per year from 2010 to 2025, per share 6.5%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | since 2015 | since 2010 | |
|---|---|---|---|
| Revenue | 62.6% | 19.7% | 14.7% |
| Revenue per share | 53.1% | 13.0% | 6.5% |
| Earnings | no data | no data | no data |
| Earnings per share | no data | no data | no data |
| Free cash flow | no data | no data | no data |
| Free cash flow per share | no data | no data | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2010 | $1.24M | −$12.48M | −$11.69M |
| 2011 | $507K | −$29.67M | −$20.29M |
| 2012 | $2.66M | −$41.41M | −$43.37M |
| 2013 | $676K | −$41M | −$32.66M |
| 2014 | $50.85M | −$7.15M | −$1.21M |
| 2015 | $1.61M | −$80.61M | −$63.84M |
| 2016 | $1.06M | −$160.11M | −$133.91M |
| 2017 | $27.52M | −$153.24M | −$134.81M |
| 2018 | $955K | −$155.65M | −$30.04M |
| 2019 | $814K | −$77.68M | −$53.52M |
| 2020 | $853K | −$111.14M | −$80.56M |
| 2021 | $200.58M | $66.98M | $92.03M |
| 2022 | $53.91M | −$116.95M | −$109.29M |
| 2023 | $91.37M | −$147.03M | −$136.72M |
| 2024 | $135.16M | −$122.31M | −$150.35M |
| 2025 | $9.68M | −$244.09M | −$163.72M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Aug 2022)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.